NEAT1 and ovarian cancer: In addition, more work on validating the therapeutic effects of in vivo knockdown of NEAT1, as well as the delivery of miR-214-3p mimics, in xenograft animal models is warranted to substantiate the potential of targeting the NEAT1/miR-214-3p axis to treat patients with ovarian cancer.